We report a case of neuropsychiatric systemic lupus erythematosus successfully treated with mycophenolate mofetil (MMF). The patient was a 40-year-old female who maintained with 7 mg of prednisolone plus 100 mg of azathioprine (AZ) per day. According to transient ischemic attack that occurred repeatedly and an elevated level of interleukin-6 (IL-6) in spinal fluid, she was diagnosed as having neuropsychiatric systemic lupus erythematosus (NPSLE). Initial increase in doses of prednisolone and AZ to 20 mg and 150 mg per day, respectively, was ineffective. After switching from AZ to MMF, her symptoms of NPSLE completely resolved with marked improvement of the IL-6 level in her spinal fluid, suggesting that MMF was effective.
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune connective tissue disease that has multiple clinical findings. When neuropsychiatric symptoms occur, the disease is called neuropsychiatric systemic lupus erythematosus (NPSLE); there is central and peripheral nervous system involvement, and the syndrome is divided into 19 groups according to clinical manifestations (1) . NPSLE is an important entity that develops during the course of the disease in 50% to 74% of SLE patients and accounts for 19% of death (2) . In cases that involve the mechanism of lupus flare (including active vasculitis), treatment with glucocorticoid, with or without cyclophosphamide (CY) pulse therapy, is warranted (3) . However, when CY is not effective or cannot be administered because of adverse effects, optimal therapy has not been established. Here we report a patient who was affected with NPSLE and had a past history of lupus nephritis with large amounts of CY. Transient ischemic attack (TIA) occurred repeatedly on azathioprine (AZ) therapy, and an elevated level of interleukin (IL)-6 in spinal fluid was recognized. Mycophenolate mofetil (MMF) that was selected as the next therapeutic agent, caused marked improvement. There have been only a few previously reported cases in which MMF was effective for NPSLE.
Case Report
The patient was a-40-year-old Japanese woman. She was found to have positive antinuclear antibody (speckled pattern, 320 titers), elevated anti-double-stranded (ds) DNA antibody, anti-SS-A antibody and lupus nephritis (type V) when she was 22 years old. Anti-Sm antibody was negative. She was treated with prednisolone 50 mg plus oral CY 50 mg per day. Due to oral CY given for 28 months (the approximately cumulative dose was 43 g), the lupus nephritis resolved and the prednisolone dose could be tapered to 10 mg per day for maintenance. The prednisolone dose was raised to 30 mg per day due to butterfly rash and hypocomplementemia when she was 36. Prednisolone could be tapered again and she was in remission with prednisolone 7 mg plus AZ 100 mg per day.
At the age of 40, she was referred to our department due to transient dysarthria and numbness in the right upper and lower extremities. On admission (day 0), her vital sign and the physical examination were unremarkable, including the neurological examination. Her body weight was 46.2 kg. Results of laboratory investigations are listed in Table. Blood cell counts were within the normal range and anti-phospholipid antibody was negative, however hypocomplementemia persisted. The brain magnetic resonance imaging (MRI) showed multiple high-brightness legions in the right cerebral hemisphere on diffusion-weighted image (DWI) (Fig. 1) , indicating cerebral infarction in the acute or subacute phase. A narrowing of the flat portion of the right middle cerebral artery was shown on magnetic resonance angiography (MRA) (Fig. 2) . Initially, atherosclerotic cerebral infarction and TIA were suspected, and we started anti-thrombin and clopidogrel after consultation with a neurologist. However, she suffered from transient paralysis of the left upper extremity the next day. After starting aspirin, symptoms were resolving, but dysarthria recurred on the 19th day of admission. Brain MRI showed new legions in the callosum on DWI, but the narrowing of the flat portion of right middle cerebral artery had disappeared, indicating reversibility of the vasoconstriction (Fig. 3) . Aspirin and clopidogrel were switched to amlodipine and cilostazol as stronger vasodilator. Abnormal lesions in the right cerebral hemisphere and callosum on MRI, could not sufficiently explain all symptoms, such as the dysarthria, weakness and numbness in upper and lower extremities. Also, she did not suffer from atrial fibrillation, valvular diseases and arterial sclerosis. We then suspected NPSLE rather than thrombosis or embolic disease. We carried out lumbar puncture and an elevated level of IL-6 in spinal fluid (33.9 pg/mL) was found. The diagnosis of NPSLE was made, and the dose of prednisolone was raised to 10 mg per day. She was discharged on the 32nd day of admission.
The brain MRI taken after one month from discharge (day 67) showed the disappearance of lesions in the callosum. We regarded this as the benefit of treatment, but transient weakness recurred about once a week from the next month (day 94). The prednisolone dose was raised to 20 mg per day (day 107), then the symptoms resolved. The IL-6 level in spinal fluid had improved (20 pg/mL) (day 127), but she came to our department complaining of transient weakness and sensory dysfunction in the right upper and lower extremities and dysarthria (day 135). We diagnosed flare of NPSLE due to a new lesion with high signal intensity on DWI, fluid attenuation inversion recovery (FLAIR), T2-weighted image (T2WI) in the right cerebellar hemisphere on brain MRI (Fig. 4) . The level of IL-6 in spinal fluid remained higher than the normal range (14.9 pg/mL). We measured the level of β2-glycoprotein (β2-GPI) Ab, lupus anticoagulant (LAC) and anti-cardiolipin IgG again to rule out antiphospholipid syndrome. The level of β2-GPI Ab was 1.3> U/mL, LAC was 1.2 and anti-cardiolipin IgG was 1 U/mL. The results were all negative again and antiphospholipid syndrome was ruled out. AZ was raised to 150 mg per day and she was discharged on the 14th day of admission (day 148). However, she was admitted to our hospital due to recurrence of the TIA (day 170). The brain MRI was normal, but the level of IL-6 spinal fluid level was increased to 19.8 pg/mL. Since prednisolone 20 mg plus AZ 150 mg per day was considered to be ineffective, we switched to prednisolone 40 mg plus MMF 2 g per day. After the switch, her symptoms disappeared completely and the prednisolone dose could be tapered to 25 mg per day. She was discharged on the 31st day of admission (day 200). Prednisolone was tapered to 20 mg per day (day 210). The level of IL-6 in spinal fluid showed marked improvement (6.0 pg/ mL) (day 225). At the time of this writing (day 322), her symptoms have not recurred. The clinical course is depicted in Fig. 5 . 
Discussion
NPSLE is a major cause of morbidity and mortality in patients with SLE (4). Cerebrovascular diseases occurred in 3-30% of NPSLE (5) and more than 80% of cerebrovascular disease comprises ischemic stroke and TIA (6) . The level of IL-6 in spinal fluid has high specificity and sensitivity to diagnose NPSLE if the cut off level is 4.3 pg/mL (7) and it is effective for evaluating disease progress.
In this case, TIA happened repeatedly. Her clinical state could be the cerebrovascular disease due to vasculitis or autoantibody associated with NPSLE, because of the upregulated spinal level of IL-6 and absence of antiphospholipid antibody, atrial fibrillation, valvular diseases and atrial sclerosis. Hypertension and a high cumulative dose of glucocorticoids were risk factors for NPSLE (6, 8) .
Vasculitis is a rare cause of cerebrovascular diseases in NPSLE (6), but there are a few reported cases which proved to be vasculitis pathologically by brain biopsy or autopsy of the lesions recognized as cerebral infarction on CT or MRI (9, 10) . In addition, autoantibodies against the nerve cell body, axon, endothelial cells and histone, for example, are frequently recognized in NPSLE patients (11, 12) . One of the pathogenic mechanisms is thought to be that these antibodies induce apoptosis and alter expression level of adhesion molecules of endothelial cells in the blood-brainbarrier, allowing the passage of toxic components and antineuronal antibodies into the central nervous system (12) . In the current case, anti-ds DNA antibody and antiphospholipid antibody were negative, but there may be other autoantibodies as yet undetected. Anti-SS-A antibody was positive in this case, however the significance of this antibody with regard to NPSLE is controversial (13, 14) .
The narrowing of right cerebral artery was reversible in the present case. The reversibility of narrowing was involved in the diagnostic criteria of reversible cerebral vasoconstriction syndrome (RCVS) that Calabrese et al. proposed (15) , but she did not meet the criteria because she did not have severe, acute headache, called "thunderclap headache" and MRA did not reveal multifocal segmental cerebral artery narrowing. It is difficult to distinguish RCVS from vasculitis (16) , but in this case, it is suggested that the narrowing of right middle cerebral artery was caused by vasculitis because the recurrence has been suppressed by MMF.
The acute management of cerebrovascular diseases in NPSLE is similar to that in the general population (6) such as antiplatelet and anticoagulant therapy. In cases where an inflammation mechanism such as vasculitis is associated with NPSLE, glucocorticoid is selected as an initial treatment. If glucocorticoid is ineffective or disease activity is high, addition of CY, which has been proven effective in some clinical trials (3, 17, 18) , may be considered (3). We could not use CY in the present case, because of the cumulative dose in the past. AZ and MMF have been used as second-line immunosuppressive drugs, but their efficacy has never been tested in clinical trials. In this case, we switched the immunosuppressant to MMF, because 150 mg of AZ per day was ineffective against NPSLE. MMF reversibly inhibits inosine-5'-monophosphate dehydrogenase (IMPDH) that controls the rate of synthesis of guanine monophosphate in the de novo pathway of purine synthesis used in the proliferation of T and B lymphocytes (19) . In addition, the type II isoform of IMPDH, which predominates in proliferating B and T lymphocytes, is about four times more sensitive to inhibition by mycophenolic acid (MPA), the prodrug of MMF, than is the type I isoform, expressed in most cell type (20) . MMF is mainly used for active lupus nephritis, but there are a few reports that MMF was effective for NPSLE. There is a report that MMF significantly decreased Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and had a glucocorticoid sparing effect among 13 SLE patients, including 2 NPSLE patients (21) . And there are two case reports of MMF effectiveness for NPSLE (one myelitis, one psychosis.) (22, 23) . However, to our knowledge, there has never been a report that MMF is effective for cerebrovascular disease in NPSLE.
In this case, various symptoms of cerebrovascular disease, such as numbness, weakness and dysarthria completely resolved and the level of IL-6 in spinal fluid decreased. Although the prednisolone dose was raised from 20 mg to 40 mg per day as induction therapy, it was tapered smoothly and has maintained the resolution of symptoms for about four months. We have not increased the prednisolone dose since MMF was started; currently, the prednisolone dose is 19 mg per day, suggesting that MMF was effective. MMF could be an option in the treatment of NPSLE.
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